Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Karmanos Cancer Center ( Site 0108), Detroit, Michigan, United States

START San Antonio ( Site 0104), San Antonio, Texas, United States

UZ Leuven ( Site 0900), Leuven, Vlaams-Brabant, Belgium

Rambam Health Care Campus ( Site 1600), Haifa, Israel

Hadassah Medical Center ( Site 1604), Jerusalem, Israel

Sourasky Medical Center ( Site 1603), Tel Aviv, Israel

N.N. Blokhin NMRCO ( Site 2101), Moscow, Moscow, Russia

Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100), Saint Petersburg, Sankt-Peterburg, Russia

Samsung Medical Center ( Site 2902), Gangnam, Seoul, South Korea

Severance Hospital, Yonsei University Health System ( Site 2901), Seodaemun-gu, Seoul, South Korea

Asan Medical Center ( Site 2900), Seoul, South Korea

Hospital Universitario 12 de Octubre ( Site 2301), Madrid, Spain

Taipei Veterans General Hospital ( Site 2800), Taipei, Taiwan

ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601), Dnipropetrovsk, Dnipropetrovsk Oblast, Ukraine

CNCE Precarpathian Clinical Oncologic Center ( Site 2600), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine